« Return to News | Clinical Intelligence

Sangamo BioSciences to present results

Friday, March 11, 2011 11:50 AM

Data from Sangamo BioSciences’ programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections (CROI).

Dr. Carl June presented preliminary data from the ongoing investigator-sponsored phase I trial at the University of Pennsylvania as well as data from Sangamo's phase I dose-escalation trial SB-728-902.  The presentation included new data from subjects on highly active antiretroviral therapy (HAART) who underwent a treatment interruption (TI) for a specified period after treatment with SB-728-T as well as subjects on HAART with undetectable virus but suboptimal CD4+ T-cell counts (200-500 cells/ mm3).

Data on preclinical ZFN-Gene modification studies was presented by Paula Cannon, Ph.D., Associate Professor of Molecular Microbiology & Immunology at the Keck School of Medicine of the University of Southern California (USC). Professor Cannon discussed Sangamo's preclinical program to develop CCR-specific ZFNs to modify the gene in hematopoietic stem cells (HSCs) to provide protection of the entire immune system from HIV infection.

Robert Doms, M.D., Ph.D., Chair, Department of Microbiology, the University of Pennsylvania School of Medicine, presented data regarding Sangamo's ZFN gene-modification program to generate CD4 T-cells that are resistant to so-called "X4-tropic" strains of HIV, strains of HIV that use the CXCR4 co-receptor to infect cells and are characteristic of late-stage HIV infections.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.